ES2418440T3 - Derivados de adamantil O-glucurónido como inhibidores de la dipeptidil peptidasa IV para el tratamiento de la diabetes - Google Patents

Derivados de adamantil O-glucurónido como inhibidores de la dipeptidil peptidasa IV para el tratamiento de la diabetes Download PDF

Info

Publication number
ES2418440T3
ES2418440T3 ES08853345T ES08853345T ES2418440T3 ES 2418440 T3 ES2418440 T3 ES 2418440T3 ES 08853345 T ES08853345 T ES 08853345T ES 08853345 T ES08853345 T ES 08853345T ES 2418440 T3 ES2418440 T3 ES 2418440T3
Authority
ES
Spain
Prior art keywords
carbon atoms
pharmaceutically acceptable
compound
inhibition
dipeptidyl peptidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08853345T
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Hassiepen
Matthias Kittelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2418440T3 publication Critical patent/ES2418440T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/17—Ink jet characterised by ink handling
    • B41J2/175—Ink supply systems ; Circuit parts therefor
    • B41J2/17593—Supplying ink in a solid state

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES08853345T 2007-11-30 2008-11-25 Derivados de adamantil O-glucurónido como inhibidores de la dipeptidil peptidasa IV para el tratamiento de la diabetes Active ES2418440T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US484607P 2007-11-30 2007-11-30
US4846P 2007-11-30
PCT/EP2008/066159 WO2009068531A2 (en) 2007-11-30 2008-11-25 Organic compounds

Publications (1)

Publication Number Publication Date
ES2418440T3 true ES2418440T3 (es) 2013-08-13

Family

ID=40679052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08853345T Active ES2418440T3 (es) 2007-11-30 2008-11-25 Derivados de adamantil O-glucurónido como inhibidores de la dipeptidil peptidasa IV para el tratamiento de la diabetes

Country Status (13)

Country Link
US (2) US8252751B2 (enExample)
EP (1) EP2247602B1 (enExample)
JP (1) JP5401465B2 (enExample)
KR (1) KR20100092461A (enExample)
CN (1) CN101918423B (enExample)
AU (1) AU2008328845C1 (enExample)
CA (1) CA2704493A1 (enExample)
ES (1) ES2418440T3 (enExample)
MX (1) MX2010005914A (enExample)
PL (1) PL2247602T3 (enExample)
PT (1) PT2247602E (enExample)
RU (2) RU2489439C2 (enExample)
WO (1) WO2009068531A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5686413B2 (ja) 2009-12-22 2015-03-18 塩野義製薬株式会社 アダマンタンアミン誘導体
CN101798270B (zh) * 2010-02-25 2013-04-17 东华大学 一种3-氨基-1-金刚烷醇的制备方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103209957A (zh) 2010-08-09 2013-07-17 盐野义制药株式会社 氨基金刚烷氨基甲酸酯衍生物的制备方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2012MU01383A (enExample) * 2012-05-04 2014-02-28
JP5929555B2 (ja) * 2012-06-28 2016-06-08 三菱瓦斯化学株式会社 ヒドロキシアダマンタンカルボン酸化合物の製造方法
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
CN103804267B (zh) * 2014-02-21 2016-06-08 张家港威胜生物医药有限公司 一种维达列汀的合成工艺
CN105439873A (zh) * 2014-08-20 2016-03-30 天津药物研究院 3-羟基-1-金刚烷胺的制备方法
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
CN104744334A (zh) * 2015-03-25 2015-07-01 合肥创新医药技术有限公司 维格列汀的制备方法
CN107311907A (zh) * 2017-07-29 2017-11-03 合肥创新医药技术有限公司 一种维格列汀异构体杂质的制备方法
CN111138334A (zh) * 2020-01-13 2020-05-12 天津民祥生物医药股份有限公司 一种维格列汀的制备方法
JP7349475B2 (ja) 2021-06-22 2023-09-22 シャープ株式会社 リレー制御回路および電源回路
EP4532466A1 (en) * 2022-06-03 2025-04-09 Universiteit Antwerpen Dpp9 binding compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7871982B2 (en) * 2005-12-09 2011-01-18 Meiji Seika Kaisha, Ltd. Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient

Also Published As

Publication number Publication date
US8252751B2 (en) 2012-08-28
CN101918423A (zh) 2010-12-15
MX2010005914A (es) 2010-12-14
WO2009068531A3 (en) 2010-09-10
US20120295860A1 (en) 2012-11-22
AU2008328845A1 (en) 2009-06-04
RU2010126056A (ru) 2012-01-10
CA2704493A1 (en) 2009-06-04
CN101918423B (zh) 2013-05-15
WO2009068531A2 (en) 2009-06-04
EP2247602B1 (en) 2013-04-03
US8569250B2 (en) 2013-10-29
PL2247602T3 (pl) 2013-08-30
AU2008328845C1 (en) 2012-11-08
RU2489439C2 (ru) 2013-08-10
RU2013119129A (ru) 2014-10-27
JP5401465B2 (ja) 2014-01-29
JP2011504903A (ja) 2011-02-17
KR20100092461A (ko) 2010-08-20
PT2247602E (pt) 2013-07-10
US20100256080A1 (en) 2010-10-07
EP2247602A2 (en) 2010-11-10
AU2008328845B2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
ES2418440T3 (es) Derivados de adamantil O-glucurónido como inhibidores de la dipeptidil peptidasa IV para el tratamiento de la diabetes
EP1638963B1 (en) N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
US7538135B2 (en) Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
KR101537148B1 (ko) 푸리논 유도체
ES2618024T3 (es) Derivado de éster de ácido carboxílico heterocíclico
JP5631387B2 (ja) Ｉａｐ阻害剤
US9242971B2 (en) Compounds for the treatment of conditions associated with DGAT1 activity
CN101326180A (zh) 哌嗪衍生物肾素抑制剂
RU2542980C2 (ru) Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
TW200904403A (en) Tricyclic aryl compounds
US20090281161A1 (en) Organic Compounds
CN101466668A (zh) 作为肾素抑制剂的吡咯烷化合物